Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

A.M. Thompson, T.G. Pickering Kidney International

RIFLE criteria for acute kidney injury

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 1 Types of coronary artery calcification

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 BMI and mortality in patients with heart failure

Figure 1 The genomic nephrology workflow: genetic diagnosis and clinical application Figure 1 |The genomic nephrology workflow: genetic diagnosis and clinical.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 2 Expression of complement activation products in renal samples

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 2 Milestones in paediatric acute kidney injury (AKI) research

Figure 1 Acute kidney injury and chronic kidney disease

Figure 1 Definition and concept of ACLF

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

The US Renal Data System “Pie Chart of Death”

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Volume 85, Issue 3, Pages (March 2014)

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Decision tree integrating the assessment,

End point Fenoldopam, n (%) Dopamine, n (%) p

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Dinna N. Cruz Advances in Chronic Kidney Disease

Volume 70, Issue 11, Pages (December 2006)

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Volume 76, Issue 6, Pages (September 2009)

Nat. Rev. Nephrol. doi: /nrneph

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Presentation transcript:

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with acute kidney disease (AKD). The severity of AKD should determine the frequency and intensity of follow-up care. Patients with more severe AKD should receive nephrology follow-up if feasible. Key modifiers that should prompt more frequent follow-up and assessment of kidney function are the presence of pre-existing chronic kidney disease, congestive heart failure, cirrhosis, and/or malignancy. Modified from Acute Dialysis Quality Initiative 16; www.adqi.org. Modified from Acute Dialysis Quality Initiative 16; www.adqi.org. Chawla, L. S. et al. (2017) Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.2